Literature DB >> 20506683

Secondary cervical cancer in a patient with chronic lymphocytic leukemia and recurrent chronic lymphocytic leukemia mimicking recurrent cervical dysplasia: a case report.

Joseph Magley1, Carolyn Moyers, Karen S Ballard, Sean Tedjarati.   

Abstract

BACKGROUND: Patients with chronic lymphocytic leukemia (CLL) have up to a 3-fold risk of site-specific secondary cancers. The only exception is a lower incidence of cervical cancer in this population. CASE: A 70-year-old, white woman with stage IV CLL was diagnosed 2 years prior to presentation with stage Ia1 squamous cell carcinoma of the cervix. Following an abnormal Pap smear, a colposcopy and biopsies were performed. Initial pathologic impression of the cervical biopsies was high grade dysplasia. The final review was consistent with CLL without cervical dysplasia.
CONCLUSION: Cervical cancer in patients with CLL is a rare occurrence. The pathologic changes on cervical epithelium caused by CLL can mimic dysplastic cellular changes. Expert pathologic review of cervical biopsies is warranted to distinguish between the diagnoses, thus altering management.

Entities:  

Mesh:

Year:  2010        PMID: 20506683

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  3 in total

1.  Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications.

Authors:  Ravi Ghanshyam Patel; Alberto Purwada; Leandro Cerchietti; Giorgio Inghirami; Ari Melnick; Akhilesh K Gaharwar; Ankur Singh
Journal:  Cell Mol Bioeng       Date:  2014-09-01       Impact factor: 2.321

2.  An Unusual Case of Chronic Lymphocytic Leukaemia Involving the Cervix.

Authors:  Jack Hamer; Maher Alazizi; Farshad Tahmasebi
Journal:  Cureus       Date:  2022-02-01

3.  Secondary Involvement of the Uterine Cervix by Nongynecologic Neoplasms: A Detailed Clinicopathologic Analysis.

Authors:  Gulisa Turashvili; Wesley R Samore; Esther Oliva; Olga Ioffe; Robert Riddell; Kay J Park; Lars-Christian Horn
Journal:  Am J Surg Pathol       Date:  2020-12       Impact factor: 6.298

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.